Comparative Pharmacology
Head-to-head clinical analysis: MYKROX versus ZAROXOLYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYKROX versus ZAROXOLYN.
MYKROX vs ZAROXOLYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MYKROX (metolazone) is a thiazide-like diuretic that inhibits sodium reabsorption in the distal convoluted tubule by blocking the Na+-Cl- cotransporter, leading to increased excretion of sodium, chloride, and water.
Inhibits sodium reabsorption in the distal convoluted tubule by blocking the thiazide-sensitive sodium-chloride symporter (NCC).
Adults: 1 mg orally once daily, preferably in the morning.
2.5 to 5 mg orally once daily; may increase up to 20 mg daily based on response.
None Documented
None Documented
Terminal elimination half-life: 50–70 hours; achieves steady-state after ~2 weeks of once-daily dosing; prolonged in hepatic impairment but not significantly altered in renal impairment.
Terminal elimination half-life ranges from 6 to 15 hours (mean ~8 hours) in patients with normal renal function. In renal impairment, half-life is prolonged and accumulation may occur.
Primarily hepatic metabolism (CYP3A4) to inactive metabolites; renal excretion accounts for <10% as unchanged drug; biliary/fecal excretion of metabolites ~75%.
Primarily renal (approximately 70% as unchanged drug and metabolites) and biliary (approximately 30% as unchanged drug and metabolites into feces).
Category C
Category C
Thiazide-like Diuretic
Thiazide-like Diuretic